Doxazosin mesylate and Agranulocytosis - a phase IV clinical study of FDA data

Summary:

Agranulocytosis is reported as a side effect among people who take Doxazosin mesylate (doxazosin mesylate), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Furosemide, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Agranulocytosis when taking Doxazosin mesylate. It is created by eHealthMe based on reports of 11,237 people who have side effects when taking Doxazosin mesylate from the FDA, and is updated regularly.

What is Doxazosin mesylate?

Doxazosin mesylate has active ingredients of doxazosin mesylate. It is often used in high blood pressure. eHealthMe is studying from 11,975 Doxazosin mesylate users. Check the latest studies of Doxazosin mesylate.

What is Agranulocytosis?

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection) is found to be associated with 2,327 drugs and 3,592 conditions by eHealthMe. Check the latest studies of Agranulocytosis.

On Jul, 18, 2026

11,237 people reported to have side effects when taking Doxazosin mesylate.
Among them, 77 people (0.69%) have Agranulocytosis.

Could Doxazosin mesylate cause Agranulocytosis?

Among these 77 people:

How long have people been on Doxazosin mesylate when they have Agranulocytosis? *

What is the gender of people who have Agranulocytosis when taking Doxazosin mesylate? *

female: 38.89 %
male: 61.11 %

What is the age of people who have Agranulocytosis when taking Doxazosin mesylate? *

What are other drugs people take besides Doxazosin mesylate? *

What are other side effects people have besides Agranulocytosis? *

Thrombocytopenia (decrease of platelets in blood): 29 people, 37.66%
Fever: 13 people, 16.88%
Leukopenia (less number of white blood cells in blood): 12 people, 15.58%
White Blood Cell Count Decreased: 10 people, 12.99%
Nausea (feeling of having an urge to vomit): 10 people, 12.99%
Fatigue (feeling of tiredness): 10 people, 12.99%
Anaemia (lack of blood): 9 people, 11.69%
Diarrhea: 8 people, 10.39%
Septic Shock (shock due to blood infection): 7 people, 9.09%
Pneumonia: 6 people, 7.79%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 11 people, 14.29%
Lung Cancer - Non-Small Cell (lung cancer): 6 people, 7.79%
Colon Cancer: 5 people, 6.49%
Burkitt Lymphoma (cancer of the lymphatic system): 4 people, 5.19%
Prostate Cancer: 4 people, 5.19%
Pain: 4 people, 5.19%
Ill-Defined Disorder: 3 people, 3.90%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 3.90%
Cerebral Infarction (less blood supply to brain resulting tissue damage): 3 people, 3.90%
Gastric Ulcer (stomach ulcer): 3 people, 3.90%

* Approximation only. Some reports may have incomplete information.

Do you take Doxazosin mesylate and have Agranulocytosis?

- Check whether Agranulocytosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Doxazosin mesylate:

Doxazosin mesylate (11,975 reports)

Agranulocytosis treatments and more:

Agranulocytosis (213,267 reports)

Browse all side effects of Doxazosin mesylate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Agranulocytosis:

Agranulocytosis (2,327 drugs)

Browse all the conditions that are associated with Agranulocytosis:

Agranulocytosis (3,592 conditions)

Related publications that referenced our studies

Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .
Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on doxazosin mesylate (the active ingredients of Doxazosin mesylate) and Doxazosin mesylate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.